Please ensure Javascript is enabled for purposes of website accessibility

Which Hot IPO Stock Is More Likely to Make You Rich: Amwell or GoodRx?

By Keith Speights – Updated Sep 29, 2020 at 11:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's not an easy decision.

Do you like to buy things that are brand spanking new? If so, you're in luck when it comes to opportunities to invest in the healthcare sector. Several healthcare companies recently conducted initial public offerings (IPOs).

Two of the hottest healthcare IPO stocks on the market right now are American Well (AMWL 5.80%) and GoodRx Holdings (GDRX -1.80%). In only a matter of days, Amwell's shares have jumped 26%, while GoodRx stock has climbed 18%. But which of these IPO stocks is more likely to make you rich going forward?

Finger pointing to the word IPO with a stock chart in the background.

Image source: Getty Images.

Great opportunities

Let's first look at the two companies' growth opportunities. Both Amwell and GoodRx operate in markets with plenty of potential.

Amwell focuses on providing telehealth services to health plans and health systems. Its clients subscribe to use the company's telehealth platform. In addition, its Amwell Medical Group (AMG) business employs more than 5,000 healthcare providers that can augment Amwell's customers' staff. 

The current addressable telehealth market for health plans and health systems totals around $12.4 billion annually. The market for AMG's services is around $18.2 billion in urgent care and $3.9 billion in telepsychiatry. Amwell's combined current market opportunity totals $34.5 billion. The company generated revenue of nearly $149 million last year.

GoodRx provides a platform for consumers that allows them to compare prescription drug prices and gives them a card for discounts on medications. The company has expanded its offerings to also include online telehealth visits with healthcare professionals and comparisons of lab testing prices.

The total addressable market for GoodRx is massive -- perhaps as big as $800 billion. Most of this opportunity focuses on lowering the cost of prescription drugs, but GoodRx also thinks that its telehealth opportunity stands at close to $250 billion annually.

Similar challenges

If Amwell and GoodRx could count on capturing significant chunks of their respective markets, both stocks would be slam dunks. However, the two companies face similar challenges.

Most importantly, other rivals are going after the same markets. Teladoc Health, for example, stands as a formidable competitor for both Amwell and GoodRx in the telehealth arena. Not only is Teladoc significantly larger than both companies, but it also offers a broader range of virtual care services that will grow even larger once its pending acquisition of Livongo Health closes. 

GoodRx's prescriptions market is highly fragmented. The good news is that the company is bigger than its competitors, which should give GoodRx an advantage in scale. However, there's a risk that pharmacy benefits managers (PBMs) or pharmacy retailers could offer products and services in the future that directly compete against GoodRx. 

Amwell faces a somewhat similar threat. The company currently partners with major electronic health record (EHR) system vendors such as Cerner. It's possible that these EHR vendors could decide to build their own telehealth functionality in the future and cut out Amwell altogether. 

The better bet

At first glance, GoodRx appears to be an easy pick over Amwell. It's already profitable, while Amwell isn't. It has a bigger addressable market. And it's the 800-pound gorilla in its core prescriptions market, while Amwell is a distant No. 2 in its core telehealth market. But there are a couple of key factors that I think tip the scales in favor of Amwell.

First, Amwell's revenue is growing at a significantly faster rate than GoodRx's revenue is. What's more, GoodRx expects that its growth rate will slow down. 

I think the opposite will be true for Amwell. The telehealth market is picking up steam, fueled by the COVID-19 pandemic. It also helps that Google is a key investor and partner with Amwell. This relationship could open up more growth opportunities for Amwell in the future. 

Second, Amwell's market cap is less than one-third that of GoodRx, while its revenue is nearly half as much as that of GoodRx. Neither stock is cheap, but GoodRx's nosebleed valuation is gushing more blood than Amwell's.

My view is that for now, at least, Amwell is more likely to make you rich over time than GoodRx is. However, I'm not recommending investors buy either stock at this point. Why? I think there are even better stocks that will make you even richer over the long run. 

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares), Livongo Health Inc, and Teladoc Health. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Livongo Health Inc, and Teladoc Health. The Motley Fool recommends Cerner. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amwell Stock Quote
$3.65 (5.80%) $0.20
GoodRx Holdings, Inc. Stock Quote
GoodRx Holdings, Inc.
$4.36 (-1.80%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.